Premium
Recent development in 2‐pyrrolidinone‐containing nootropics
Author(s) -
Gamzu Elkan,
Hoover Toni M.,
Gracon Stephen I.,
Ninteman Monica V.
Publication year - 1989
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430180302
Subject(s) - placebo , central nervous system , clinical trial , neuroscience , cognition , medicine , psychology , pharmacology , pathology , alternative medicine
This paper reviews the development of the concept of nootropics‐‐compounds whose activity appears to be specific to enhancement and protection of those functions of plasticity of the central nervous system that we now call cognition. The rest of the review focuses on clinical and preclinical results reported on 2‐pyrrolidinone‐containing noortropics since 1986. Although the clinical efficacy of these compounds remains to be proved definitively, there are some double‐blind trials that demonstrate superiority against placebo. Preclinically, a wide variety of laboratories continue to demonstrate and expand protective effects of nootropics against various insults of the CNS.